Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Method of regulating cell metabolism or physiology
Reexamination Certificate
2001-06-06
2003-07-01
McGarry, Sean (Department: 1635)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Method of regulating cell metabolism or physiology
C435S377000, C536S023100, C536S024500, C536S024100, C514S04400A
Reexamination Certificate
active
06586244
ABSTRACT:
TECHNICAL FIELD
The invention provides compositions and methods for inhibiting laminin5beta3 gene expression and/or biological activity. Such compositions and methods find utility in the treatment of cancers, particularly of epithelial origin.
BACKGROUND OF THE INVENTION
A number of cancers derive from epithelial cells, including some colon cancers and breast cancers. Laminin is a secreted protein that plays a role in normal cell function by interacting with its integrin receptors. Laminins are heterotrimeric basement membrane molecules that mediate important cell functions including adhesion, migration and differentiation. Laminin5gamma2 has been found to play a role in cell adhesion of human keratinocytes and mouse squamous carcinoma cells. (Salo, S. et al.,
Matrix Biol.
18:197-210, 1999.) Alteration of laminin-5 expression was reported in development of squamous cell carcinomas. (Thorup, A. K. et al.,
A.P.M.I.S.
106:1170-1180, 1998.) Because of the role played by proteins of the laminin family in cancer cell development, there is a need in the art for materials and methods for regulating laminin expression and function, thereby providing new methods for cancer treatment and prevention.
SUMMARY OF THE INVENTION
The present invention provides, in one embodiment, inhibitors of laminin5beta3. Inventive inhibitors include, but are not limited to, antisense molecules, ribozymes, antibodies or antibody fragments, human monoclonal antibodies, proteins or polypeptides as well as small molecules. Exemplary antisense molecules comprise at least 10, 15 or 20 consecutive nucleotides of or hybridize under stringent conditions to the nucleic acid of SEQ ID NO: 1. More preferred are antisense molecules that comprise at least 25 consecutive nucleotides of or hybridize under stringent conditions to the sequence of SEQ ID NO:1. Representative antisense molecules are provided herein as SEQ ID NO:2 and 3.
In further embodiments, compositions are provided that comprise one or more laminin5beta3 inhibitor in a pharmaceutically acceptable carrier.
Additional embodiments provide methods of decreasing laminin5beta3 gene expression or biological activity.
Each of the methods of the present invention have in common the administration of one or more inventive laminin5beta3 inhibitor to a mammalian cell.
REFERENCES:
Sudhir Agrawal, TIBTECH, Oct. 1996, vol. 14, pp. 376-387.*
Andrea D. Branch, TIBS 23—Feb., 1998.*
Kuang-Yu Jen et al., Stem Cells 2000; 18: pp. 307-319.*
Bouatrouss et al., “Altered Expression of Laminins in Crohn's Disease Small Intestinal Mucosa,”American Journal of Pathology 156(1):45-50, Jan. 2000.
Karabulut et al., “Can alterations in integrin and laminin-5 expression be used as markers of malignancy?,”APMIS 106:1170-1180, 1998.
Koshikawa et al., “Overexpression of Laminin &ggr;2 Chain Monomer in Invading Gastric Carcinoma Cells,”Cancer Research 59:5596-5601, Nov. 1, 1999.
Lohi et al., “Basement membrane laminin-5 is deposited in colorectal adenomas and carcinomas and serves as a ligand for &agr;3&bgr;1integrin,”APMIS 108:161-172, 2000.
Salo et al., “Laminin-5 promotes adhesion and migration of epithelial cells: identification of a migration-related element in the &ggr;2 chain gene (LAMC2) with activity in transgenic mice,”Matrix Biology 18:197-210, 1999.
Skyldberg et al., “Laminin-5 as a Marker of Invasiveness in Cervical Lesions,”Journal of National Cancer Institute 91(21):1882-1887, Nov. 3, 1999.
Den-Otter Douglas R.
Jefferson Anne B.
Reinhard Christoph J.
Winter Jill A.
Blackburn Robert P.
Chiron Corporation
McGarry Sean
Morley Kimberlin L.
Potter Jane E. R.
LandOfFree
Compositions and methods for treating neoplastic disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating neoplastic disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating neoplastic disease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3099094